|
Synonyms: ABX-EGF | ABX-EGF Mab | Vectibix®
panitumumab is an approved drug (FDA (2006), EMA (2007))
Compound class:
Antibody
Comment: Binds to and competitively inhibits the activity of the epidermal growth factor receptor.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Used to treat EGFR-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Competitively inhibits the binding of ligands to the epidermal growth factor receptor on both normal and tumour cells. This in turn prevents the receptor autophosphorylation induced by these ligands and the activation of kinases leading to inhibition of cell growth, decreased pro-inflammatory cytokine and vascular growth factor production, and internalisation of the receptor. |
| External links |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |
